Imaging-Derived Sarcopenic Obesity and Cardiovascular Outcomes: Insights Into Heart Failure Risk and Muscle Biology

Sanghvi MM, Nicholls HL, Kaplan TM, et al.

Journal of the American College of Cardiology, 2026

Clinical Implications of Mounjaro (Tirzepatide) for Breast Cancer Detection and Management: A Narrative Review

Mady R, Tafazal H, Soliman H, et al.

Cureus, 2026;18(6):e111445

Impact of tirzepatide on systemic arterial stiffness assessed by cardio-ankle vascular index in individuals with obesity complicated by type 2 diabetes: A retrospective cohort study in Japan

Nagayama D, Wakamatsu M, Watanabe Y, et al.

Obesity pillars, 2026;19:100291

Auditable large language model curation of clinical notes refines glucagon-like peptide-1 initiation, persistence ascertainment, and compounding use beyond prescription records

Varma G, Murugadoss K, Kurian ME, et al.

Biology methods & protocols, 2026;11(1):bpag035

Peritoneal Incretin Deficiency and Tirzepatide as a Multi-Axis Adjuvant Hypothesis in Treatment-Refractory Endometriosis: A Mechanistic Framework Linking Metabolism, Immunity, Fibrosis, and Nociception

Jacobsen L, Viana DPDC, Folador GM, et al.

International journal of molecular sciences, 2026;27(13)

Development and Validation of a Liquid Chromatography/Tandem Mass Spectrometry Method for the Quantification of the GLP-1 Analog Semaglutide in Rat Plasma, and Its Application in a Pharmacokinetic Study

Kim JM, Kim KA, Yu NY, et al.

Pharmaceutics, 2026;18(7)

Tirzepatide

Brož J, Koželuhová M, Michalec J, et al.

Ceska a Slovenska farmacie : casopis Ceske farmaceuticke spolecnosti a Slovenske farmaceuticke spolecnosti;75(2):112-116

Real-world weight loss with injectable semaglutide vs dulaglutide for diabetes

Spitery A, Lobkovich A, Thomas E

The American journal of managed care;32(6):328-333

Erratum

Obesity facts, 2026;:1

Experience with Tirzepatide and Weight Management During and After a Clinical Trial in Japanese Patients with Obesity Disease: A Qualitative Study

Kiyosue A, Sato M, Cai Z, et al.

Advances in therapy, 2026

Semaglutide for Primary Prevention of Major Adverse Cardiac and Cerebrovascular Events in Patients with Type 2 Diabetes and Comorbid Rheumatoid Arthritis: A Target-Trial Emulation

Malik F, Shah M, Chang Y, et al.

European heart journal. Cardiovascular pharmacotherapy, 2026

Hepatic Safety of Orforglipron in Adults With Obesity or Overweight and/or Type 2 Diabetes: A Pooled Analysis of the Orforglipron Phase 3 Clinical Trials

Wharton S, Stefanski A, Chen J, et al.

Diabetes, obesity & metabolism, 2026

Efficacy and Safety of GLP-1 Receptor Agonists on Combined Cardiovascular and Renal Outcomes in Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis

Kaur R, Singh A

Diabetes, obesity & metabolism, 2026

The Impact of Missed Doses on Pharmacokinetic Concentrations for Oral Semaglutide in Comparison to Other Glucagon-Like Peptide-1-Based Therapies

Overgaard RV, Agersø H, Hollensen C, et al.

Diabetes, obesity & metabolism, 2026

Semaglutide treatment in MOSH is associated with altered DNA methylation patterns of genes related to glycolipid metabolism

Guo Y, Su J, Shen L, et al.

Scientific reports, 2026

Weight loss and cardiovascular outcomes with incretin-based therapies after metabolic and bariatric surgery: a nationwide US cohort study

Gillikin A, Lee Y, Varney C, et al.

EClinicalMedicine, 2026;97:104033

Semaglutide alleviates osteoarthritis independent of weight loss via GLP-1R-mediated activation of autophagy through AKT/mTOR inhibition

Lin J, Luo M, Tang H, et al.

Journal of orthopaedic translation, 2026;59:101166

Ironing Out Possible Micronutrient Deficiencies Associated with Incretin Receptor Agonist-Based Therapies: Proposed Practical Strategies to Prevent and Manage Iron Deficiency

Infante M, Ricordi C, Pacifici F, et al.

Nutrients, 2026;18(13)

GLP-1 and Alcohol-Related Behaviors: Insights From Preclinical Studies

Jerlhag E

Biological psychiatry, 2026

Efficacy and Safety of Once-Weekly Semaglutide Versus Basal Insulin and Other GLP-1 Receptor Agonists in Adults With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs: A Systematic Review and Pairwise Meta-Analysis

Aljulajil FA, Rabbani U

Cureus, 2026;18(6):e111363